论文部分内容阅读
干扰素对慢性乙型肝炎病毒(HBV)感染患者的疗效已获肯定,但由于 HBV 携带者的个体异质性,其治疗的成功率为25～50%之间。病人和方法作者随机选择114例有详细病史、治疗开始6个月内作肝活检、治疗第1天作各项生化免疫检测、病程在6个月以上的慢性 HBV 携带者,用重组α-干扰素-2α或类淋巴母细胞α-干扰素治疗。按每周3次至少12周,每例病人的最低剂量为9千万(9～36.5千万)U/M~2。分成三组治疗,并把三组相似受试者的结果混合统计分析,以了解哪些指标可预测 HBV 感染者对α-干扰素的治疗效果。
The efficacy of interferon in patients with chronic hepatitis B virus (HBV) infection has been affirmed, but due to the individual heterogeneity of HBV carriers, the success rate of treatment of 25% to 50%. Patients and Methods The authors randomly selected 114 patients with a detailed history of liver biopsy within 6 months of treatment, the first day of treatment for biochemical immunodeficiency, duration of more than 6 months of chronic HBV carriers, with recombinant α-interference Alpha-2 alpha or lymphoblastoid alpha-interferon therapy. 3 times a week for at least 12 weeks, the minimum dose for each patient is 9 million (9 ~ 36.5 million) U / M ~ 2. Divided into three groups and mixed statistical analysis of the results from three groups of similar subjects to find out which of these predictors of IFN-alpha in HBV-infected patients.